Children on dialysis who have anemia and require high doses of drugs to treat it are at increased risk of dying prematurely.
Completely correcting anemia in kidney transplant recipients may preserve kidney function better than partially correcting anemia.
When using ESAs to correct anemia in patients with chronic kidney disease, focus less on hitting a given hemoglobin target.
Decreasing TSAT and higher ESA doses are associated with increasing platelet counts.
Folic acid treatment significantly improved hemoglobin levels and decreased epoetin alfa use.
Elemental iron requirement was reduced by half in patients receiving ferric citrate versus an active control.
These include use of lower ESA doses and hemoglobin levels.
Weekly dose of erythropoiesis-stimulating agents decreased and hemoglobin levels increased.
Patients with levels below 10 g/dL had the highest unadjusted mortality and all-cause hospitalization rates.
A transferrin saturation of 20% or less was associated with a 2.2 times increased risk of death from any cause.
Study also documents use of higher IV iron doses and declining hemoglobin levels.
Plasma ascorbic acid levels in the physiologic range correlated inversely with EPO resistance.
Soluble ferric pyrophosphate is a unique carbohydrate-free formulation administrated via dialysate.
Soluble ferric pyrophosphate significantly decreased ESA use while maintaining target hemoglobin levels without increasing iron stores.
The trend is most pronounced among Medicare recipients since the debut of bundling, ESA labeling changes.
Study also showed an increase in the proportion of patients with hemoglobin level below 10 g/dL and in transfusion rates.
Voluntary recall of anemia drug due to reports of anaphylaxis, including three deaths
Preoperative anemia associated with elevated risk of deaths from other illnesses.